F351-0352 Screening compound: 1-(2,1,3-benzothiadiazole-4-sulfonyl)-7'-fluoro-5'H-spiro[piperidine-4,4'-pyrrolo[1,2-a]quinoxaline]

F351-0352 Screening compound: 1-(2,1,3-benzothiadiazole-4-sulfonyl)-7'-fluoro-5'H-spiro[piperidine-4,4'-pyrrolo[1,2-a]quinoxaline]
F351-0352 Screening compound: 1-(2,1,3-benzothiadiazole-4-sulfonyl)-7'-fluoro-5'H-spiro[piperidine-4,4'-pyrrolo[1,2-a]quinoxaline] alternative view

Chemical Structure Depiction of ChemDiv screening compound F351-0352
1-(2,1,3-benzothiadiazole-4-sulfonyl)-7'-fluoro-5'H-spiro[piperidine-4,4'-pyrrolo[1,2-a]quinoxaline]

Available from 1 mg

Formats:

  • Glass Vials (4ml Glass Vials VWR #97047-678)
  • 96-tube racks (Matrix #4247 96-well 1.4ml sealed with capmats, empty cols 1 & 12, 100uL of 10mM)

Shiptime: 1 week worldwide delivery in most cases

Compound Identifiers

ChemDiv Compound ID

F351-0352

Molecular Formula

C21H18FN5O2S2 (C21 H18 FN5 O2 S2)

Compound Name

1-(2,1,3-benzothiadiazole-4-sulfonyl)-7'-fluoro-5'H-spiro[piperidine-4,4'-pyrrolo[1,2-a]quinoxaline]

IUPAC name

1-(213-benzothiadiazole-4-sulfonyl)-7'-fluoro-5'H-spiro[piperidine-44'-pyrrolo[12-a]quinoxaline]

SMILES

O=S(c1cccc2nsnc12)(N(CC1)CCC11Nc(cc(cc2)F)c2-n2c1ccc2)=O

InChI

InChI=1S/C21H18FN5O2S2/c22-14-6-7-17-16(13-14)23-21(19-5-2-10-27(17)19)8-11-26(12-9-21)31(28,29)18-4-1-3-15-20(18)25-30-24-15/h1-7,10,13,23H,8-9,11-12H2

InChI Key

MHBYROFEZZFMIG-UHFFFAOYSA-N

MDL Number (MFCD)

MFCD14951538

Chemical and Physical Properties

Saltdata

n/a

Molecular Weight

455.54

Hydrogen Bond Acceptors Count

7.00

Hydrogen Bond Donors Count

1.00

Rotatable Bond Count

2.00

Number of Nitrogen and Oxygen Atoms

7

Partition Coefficient, logP

4.488

Distribution Coefficient, logD

4.488

Water Solubility, LogSw

-4.38

Polar Surface Area

66.409

Acid Dissociation Constant (pKa)

17.56

Base Dissociation Constant (pKb)

2.55

Number of Chiral Centers

0.00

Percent sp3 carbon bonding

23.80

F351-0352 in Drug Discovery

Included in Screening Libraries

Anticancer Library (62698 compounds)

300k Representative Compounds Library (Bemis-Murcko Clustering Algorithm) (286253 compounds)

KRAS-Targeted Library (16000 compounds)

Protein-Protein Interaction Library (218420 compounds)

Spiro Library (21655 compounds)

Targeted Diversity Library (40567 compounds)

Akt-Targeted Library (14764 compounds)

Beyond the Flatland Library sp3 enriched (92988 compounds)

Included in 1.7M Stock Database

Therapeutical areas:
  • Cancer
  • Cancer
  • Digestive system
  • Respiratory tract
  • Otorhinolaryngologic
  • Digestive system
  • Respiratory tract
  • Male
  • Female
  • Hemic and lymphatic
  • Skin
Targets:
  • Kinases
  • Kinases
Mechanism of action:
  • PPI modulators
  • PPI modulators
Structure:
  • Cyclic compounds
  • Cyclic compounds

References: we are preparing a list of scientific research reports with F351-0352 chemical compound. It will be published here after verification.

Frequently Asked Questions

How to purchase chemical compound F351-0352?
Check Price and Availability of F351-0352, then you can add required amount to the Shopping Cart. In the Shopping Cart you can again refine your selection. Once you are sure that it’s exactly what you want you can move forward with the Checkout (to pay online by credit card, or via PayPal), or Request a Quote.
What is the minimum amount of F351-0352 you sell to drug discovery company or institution?
Available from 1 mg in Glass Vials or 96-tube racks.
Delivery options for F351-0352
ChemDiv sends parcels with Express services (UPS, WC).
  • 1–2 days for small orders
  • 2–4 weeks for large selections
Delivery formats for F351-0352
  • 0.5–50 mg of dry powder sample in single glass vials, custom vials
  • DMSO solutions frozen 10μl–250μl@10mM (96 and 384 format)

Custom synthesis of F351-0352 available by request